Anupam Rasayan India Ltd. · NSE:ANURAS
Anupam Rasayan India — Q2 & H1 FY24 Earnings Presentation
25 slides from Anupam Rasayan India's earnings presentation, Nov 7, 2023
Slide 1: Exchange filing cover letter - Investor Presentation
ANUPAM RASAYAN INDIA LTD. R ARILSLDSTX20231107081 Date: November 07, 2023 To, To, BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Dalal Street, ‘Exchange Plaza’, C-1, Block-G, Mumbai -400001, India Bandra Kurla Complex SCRIP CODE: 543275 Bandra (East), Mumbai 400051,
Slide 2: Anupam Rasayan India Limited Q2 & H1FY24
$," j@ ANUPAM RASAYAN INDIA LIMITED Anupam Rasayan India Limited Q2 & H1FY24 NOVEMBER 2023
Slide 3: Quarterly Highlights
Quarterly Highlights 1 2 Anupam Rasayan India Limited \
Slide 4: Quarterly Financial Highlights
3 Quarterly Financial Highlights \ Limited India Consolidated Total Consolidated EBITDA (Incl. Consolidated PAT stood Rasayan Revenue was ₹3,956 Mn; Other Revenue) was ₹ 1,109 at ₹ 487 Mn., margin Y-o-Y growth of 3.25% Mn.; margin stands at 28% stands at 12% Anupam Standalone Total Revenue Standalon
Slide 5: Managing Director's Message
4 I Managing Director’s Message \ Limited “Amidst the challenging external environment, I am happy that we have been able to India hold our ground and deliver some growth. Our total revenue for the first half of FY24 reached Rs. 794 crores, reflecting a robust year-over-year growth of 11%. Our stron
Slide 6: Operational Updates
5 Operational Updates \ Limited India Commercialization of New Molecules – In Q2FY24, commercialized 3 new molecules were commercialized taking total to 5 new molecules commercialized in H1FY24, with total of 10 new molecules to be launched in FY24. Of the total 3 molecules, 1 molecule is Rasayan fr
Slide 7: Quarterly Financials: Consolidated Profit & Loss Summary
6 QUARTERLY FINANCIALS I Consolidated Profit & Loss Summary \ Limited (All amounts are in ₹ Mn) Q2FY24 Q2FY23 INCOME India Revenue from Operations 3,921 3,928 Other Income 35 (96) Rasayan Total Revenue 3,956 3,831 Total Revenue Growth (%) 3% EXPENSES: Anupam Cost of Raw Materials Consumed 1,625 1,61
Slide 8: Quarterly Financials: Standalone Profit & Loss Summary
7 QUARTERLY FINANCIALS I Standalone Profit & Loss Summary \ Limited (All amounts are in ₹ Mn) Q2FY24 Q2FY23 INCOME India Revenue from Operations 3,171 3,140 Other Income 35 (53) Rasayan Total Revenue 3,206 3,087 Total Revenue Growth (%) 4% EXPENSES: Anupam Cost of Raw Materials Consumed 1,237 1,155
Slide 9: Half Yearly Financials: Consolidated Profit & Loss Summary
8 HALF YEARLY FINANCIALS I Consolidated Profit & Loss Summary \ Limited (All amounts are in ₹ Mn) H1FY24 H1FY23 INCOME India Revenue from Operations 7,785 7,299 Other Income 158 (124) Rasayan Total Revenue 7,944 7,175 Total Revenue Growth (%) 11% EXPENSES: Anupam Cost of Raw Materials Consumed 3,256
Slide 10: Half Yearly Financials: Standalone Profit & Loss Summary
9 HALF YEARLY FINANCIALS I Standalone Profit & Loss Summary \ Limited (All amounts are in ₹ Mn) H1FY24 H1FY23 INCOME India Revenue from Operations 6,055 6,238 Other Income 134 (179) Rasayan Total Revenue 6,189 6,058 Total Revenue Growth (%) 2% EXPENSES: Anupam Cost of Raw Materials Consumed 2,337 2,
Slide 11: Business Overview
Business Overview 2 10 Anupam Rasayan India Limited \
Slide 12: Company at a glance
11 Innovating Sustainable & Custom Solutions for Global Markets \ Limited Company at a glance India Established Custom Specializes in multi-step Catering to globally Strong supply chain Synthesis player with 39 synthesis undertaking relevant chemical & with backward Rasayan years of track record com
Slide 13: Evolution of Anupam Rasayan
12 I Evolution of \ Phase II- Limited Phase I-Inception Anupam The Acceleration 2023 India • Raised ₹5,000 mn. 1984 through QIP Formed Rasayan • Commissioned Solar partnership firm ANUPAM RASAYAN INDIA LTD. Power Plant of 5.4MW “Anupam Rasayan” at Bharuch • Fast growing Anupam 2022 Specialty Chemica
Slide 14: Chemical Conduits and Global Partnerships
13 I Chemical Conduits and Global Partnerships \ Limited India Business Verticals Overview Few of our top global clients Geography-Wise Revenue Rasayan Life Science Related Other Specialty Specialty Chemicals Chemicals FY23 ■ EUROPE 30% ■ INDIA 36% Agrochemicals l syngenta ■ SINGAPORE Anupam Special
Slide 15: Charting New Frontiers with R&D Excellence
14 I Charting New Frontiers with R&D Excellence \ Limited Process technologies deployed India Flow Chemistry Photo Chemistry • Reduced lead time • Simplified Rasayan • Material efficient & synthesis of cost benefits complex molecules • Lesser • Larger potential for environmental automation impacts i
Slide 16: Experienced Leadership & Deep Technical Talent Pool
15 I Experienced Leadership & Deep Technical Talent Pool \ Limited Experienced management team Mr. Gopal Agrawal Mr. Ravi Desai India Chief Executive Officer Sales Head Qualified CA with 25+ yrs. Exp in 20+ years of experience; with Corporate Strategy, global M&A and ARIL since 2012 0 Rasayan Mgmt C
Slide 17: Expanded Business Development Team Globally
16 Expanded Business Development Team Globally \ Limited Europe United States India Mr. Thierry Baumlin Mr. Pierre Joris Mr. John Grant Rasayan Key Account Manager - Business Advisor - Business Advisor - Crop Protection Specialty Fluoro Chemicals Specialty Fluoro Chemicals 30 years+ of experience in
Slide 18: Growth Drivers
Drivers Growth 3 17 Anupam Rasayan India Limited \
Slide 19: Growth Drivers
18 Growth Drivers \ Limited India Rasayan 1 2 3 Anupam Growth of Execution of Expansion in Product Signed LOIs and Fluorination Portfolio Contracts chemistry
Slide 20: Growth Of Product Portfolio
19 I Growth Of Product Portfolio \ Limited New Strategic Custom 90+ 10+ India Development Products under pipeline to be manufactured by Number of molecules Number of molecules to be Rasayan Anupam in India: in R&D and Pilot commercialised in FY24 Anupam Agro Pharma • Established Active Ingredients o
Slide 21: Strong Order Book - Recent LOI/Contracts Signed
20 I Strong Order Book – Recent LOI/Contracts Signed \ Limited Signing Quarter Segment Customer LOI/Contract Tenor (Years) Value(₹ Crores) India Q1FY22 Life Science Multinational Life Science Company LOI 5 ₹1,100 Q1FY22 Life Science Two Multinational Companies Contract 5 ₹540 Rasayan Q2FY22 Life Sci
Slide 22: Strategic Expansion in Fluorination with Tanfac
21 I Anupam’s Strategic Expansion in Fluorination with Tanfac \ Limited Anupam acquired ~26% stake in India Tanfac for ~₹1,530M in May'22 to Rasayan TANFAC Producer of Leading Anupam fluorinated producer of intermediates KF/HF • Specialty fluoride chemical Anupam Tanfac manufacturer in India Only In
Slide 23: Expansion in Fluorination Chemistry
22 I Expansion in Fluorination Chemistry \ Limited FOCUSED SEGMENTS MOLECULES END APPLICATION CUSTOMER SEGMENT REVENUE India POTENTIAL Product A Elastomer US MNC Rasayan Polymers $ 40 – 70 Mn. Product B Semiconductor/Flame Retardant Japanese MNC Anupam Product X/Y Cardio/Anti-viral Indian MNC Pharma
Slide 24: Summary: Strengths and Key Highlights
23 Summary \ Limited Strengths and Key Highlights India • Doubled manufacturing capacity in the last three years Rasayan Manufacturing • Strong capex plans to expand capacity into newer Prowess molecules / chemistries Anupam R&D • DSIR recognized R&D center with a team of 88 R&D professionals Capabi
Slide 25: Thank You
Corporate Office ANUPAM Anupam Rasayan India Ltd. India (HQ) 10th Floor, Icon Rio, Dumas Road, Surat, Gujarat, RASAYAN INDIA India – 395 007 LIMITED ThankYou BSE: 543275 | NSE: ANURAS | ISIN: INE930P01018 ©2022 – Anupam Rasayan India Limited, All Rights Reserved. DRAFT
Anupam Rasayan India — Q2 & H1 FY24 Earnings Presentation on 6ix